Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalizumab + Radiotherapy in Recurrent/Metastatic Adrenal Cortical Carcinoma
NCT06587802Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in adrenocortical carcinoma (ACC), sponsored by Sun Yat-sen University. Started Mar 2025; status: recruiting.
02
Drugs
toripalimab
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT06587802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06587802.